PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target
Authors:
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2017YFC0908003, 2017YFC0908004, 18ZXDBSY00020)
- Tianjin Medical University (2017ZDSYS12)
This publication has 22 references indexed in Scilit:
- Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancerInternational Journal of Oncology, 2014
- Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells inCCNE1-Amplified Ovarian CancerClinical Cancer Research, 2013
- Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancerProstate Cancer and Prostatic Diseases, 2012
- DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate CancerDNA and Cell Biology, 2012
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- WGCNA: an R package for weighted correlation network analysisBMC Bioinformatics, 2008
- R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated InflammationThe Journal of Pharmacology and Experimental Therapeutics, 2006
- A General Framework for Weighted Gene Co-Expression Network AnalysisStatistical Applications in Genetics and Molecular Biology, 2005
- Myt1: A Membrane-Associated Inhibitory Kinase That Phosphorylates Cdc2 on Both Threonine-14 and Tyrosine-15Science, 1995
- Principles of CDK regulationNature, 1995